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ABSTRACT
 
Objectives:
 
Febrile neutropenia (FN) in patients with
cancer treated with chemotherapy has traditionally been
managed with inpatient broad-spectrum antibiotics until
the infection and neutropenia have resolved. A newer
strategy is outpatient oral or intravenous antibiotics in
selected patients after an initial hospitalization. We
sought to determine these costs, both overall and relative
to those of traditional management, and the optimal role
of prophylactic colony-stimulating factor (CSF) in
patients at greatest risk for FN.
Methods: Existing economic decision models were mod-
iﬁed by incorporating a treatment strategy for FN in
which patients are classiﬁed as high- and low-risk accord-
ing to criteria described by Talcott. Low-risk patients
were assumed to be treated as outpatients. Overall costs
with the revised economic model were assessed and sen-
sitivity analyses were performed.
Results: The costs of an episode of FN were estimated as
1) no CSF: $13,355; 2) CSF with hospitalization for FN:
$8677; and 3) CSF with risk stratiﬁcation and outpatient
management in low-risk patients: $8188. The risk
threshold for the cost-effective use of CSF was only
slightly lower with outpatient treatment. When all
patients with FN are treated as inpatients and the cost of
hospitalization is $1750/day the risk threshold for FN at
which prophylactic CSF becomes cost-effective is 16%.
It is 15% when low-risk patients are treated as
outpatients.
Conclusions: Outpatient treatment slightly decreases
the risk threshold for FN at which prophylactic CSF
becomes cost-effective. The limited economic effect of
this strategy may be because the patients who were at
greatest risk of complications had signiﬁcantly longer
lengths of stay and accounted for most of the hospitali-
zation costs.
Keywords: cost minimization, febrile neutropenia, growth
factors, neutropenia, outpatient, pharmacoeconomics,
risk model.
 
Introduction
 
Myelosuppression, especially neutropenia, is the
major dose-limiting toxicity of cancer chemother-
apy, and the risk of infection and mortality increases
with the severity and duration of the neutropenia.
Patients with febrile neutropenia (FN) are typically
managed with immediate hospitalization for assess-
ment, cultures, and the administration of intra-
venous (IV) broad-spectrum antibiotics [1].
Traditionally, patients remain hospitalized and are
treated with antibiotics until the fever and any signs
of active infection have resolved and the absolute
neutrophil count has recovered.
Randomized controlled trials (RCTs) have estab-
lished that prophylactic recombinant human col-
ony-stimulating factor (CSF) reduces the severity
and duration of neutropenia, as well as the inci-
dence of complications such as FN [2–5]. A recent
meta-analysis of data from eight RCTs of prophy-
lactic CSF has conﬁrmed its clinical efﬁcacy in many
different malignancies and treatment regimens [6].
The cost of CSF, along with its widespread clin-
ical use, has led to a number of economic analyses
and the development of clinical practice guidelines
for its use [7–10]. Early cost-minimization models
that considered only direct inpatient medical costs
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of $1000 per day produced a risk threshold for FN
of 40%, suggesting that an economic beneﬁt can be
obtained by administering CSF to patients with a
risk of developing FN of 40% or greater [7]. More-
recent economic evaluations updated to reﬂect
more-current hospitalization costs of $1750 per day
have produced risk thresholds closer to 23%, and
this number is reduced further to about 18% when
indirect costs associated with loss of productivity
are included in the analysis [5,11].
Alternatives to inpatient IV antibiotics for man-
aging FN have received greater attention in the past
several years as a way of reducing the costs of treat-
ing FN. These alternatives include inpatient oral
antibiotics, early discharge with either oral or IV
antibiotics, and entirely outpatient antibiotics [12].
These methods reduce the costs of hospitalization
and can be more convenient for the patient. There
remain some risks of life-threatening complications
(septicemia and nephrotoxicity), however, and poor
patient adherence with oral antibiotic regimens is
common [13,14]. In addition, the safe and effective
management of patients with FN in the outpatient
setting requires considerable infrastructure and
thorough patient selection that considers distance
from the clinic, caregiver availability, and adher-
ence. Finally, maximizing the effectiveness of these
treatment strategies requires determining which
patients are most likely to beneﬁt from them. Sev-
eral studies have classiﬁed patients with neutrope-
nia into risk categories for planning outpatient
treatment [13–15].
The method described by Talcott was shown to
determine an initial treatment regimen for FN
(inpatient instead of outpatient antibiotics) that
resulted in fewer than 20% of the patients treated as
outpatients be admitted (i.e., treatment failures in
an outpatient setting). Talcott noted that the outpa-
tient management of FN was not without risks and
that the differences in the costs of care between
these inpatient and outpatient treatment options
had not been thoroughly considered [14].
The Multinational Association of Supportive
Care in Cancer (MASCC) recently developed a scor-
ing system for determining which patients with FN
are at low risk for serious medical complications
[15]. The MASCC scoring system is more sensitive
and has lower overall misclassiﬁcation rates than
Talcott’s system, but it is more difﬁcult to use.
Because lower treatment costs are expected with
outpatient management, it would be reasonable to
expect this to have an effect on the risk threshold
for FN at which CSF becomes cost-effective. If the
treatment costs were signiﬁcantly lower, as in early
discharge models or outpatient-treatment models,
then the likelihood of FN would have to be much
greater to offset the costs of CSF. We conducted an
economic analysis of CSF prophylaxis that used a
cost-minimization model to assess the effect of
using an outpatient treatment strategy based on
categorizing patients with FN for their risk of
hospitalization.
 
Methods
 
A decision model (Fig. 1) was developed to evaluate
the effect of prophylactic CSF on overall treatment
costs with and without an option for outpatient
treatment in patients with FN who are at low risk
for serious medical complications, based on the cat-
egorization proposed by Talcott [14]. The analysis
uses a standard decision model based on decision
theory. The decision choices are 1) chemotherapy
without the use of CSF (control); and 2) chemother-
 
Figure 1
 
Decision tree for evaluating the
overall treatment costs of  FN.
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apy with prophylactic CSF; i.e., CSF given after the
completion of a cycle of chemotherapy and stopped
on neutrophil recovery. The model assumes that all
patients with FN will be hospitalized and be treated
with empiric iv antibiotics. In the decision choice
for prophylactic CSF in managing FN two choices
were assumed. The ﬁrst is the standard practice of
keeping all patients in the hospital until the FN has
resolved. The second is that patients are stratiﬁed
into FN risk groups that include an option for out-
patient treatment of the low-risk patients (Table 1).
Low-risk patients are those classiﬁed as Talcott’s
group 4 (stable patients without comorbidities and
with responsive cancers). Patients who were in Tal-
cott’s groups 1 through 3 were combined in one
“high-risk” category.
A limited validation of Talcott’s classiﬁcation of
patients with FN was undertaken in 82 consecutive
patients who were admitted to Albany Medical
Center between 1998 and 1999. Patients were clas-
siﬁed as high- or low-risk, and the average hospital
length of stay (LOS) was calculated.
Baseline model probabilities and cost estimates
are shown in Table 2. The estimates for the risk of
hospitalization for FN (0.55) and the reduction in
the risk of developing FN with CSF (0.50) are based
on the results in an early clinical trial of the efﬁcacy
of CSF [17]. We have used these estimates that were
also used in our earlier study to allow comparisons
with our previous model [5]. These baseline proba-
bilities are, however, consistent with the results of a
meta-analysis of data from RCTs of prophylactic
CSF that reports a risk of hospitalization of 0.51
(95% conﬁdence interval [CI] 0.47–0.55) and a
reduction in the risk of developing FN with FN
(odds ratio 0.38, [95% CI 0.29–0.49]) [6]. It should
be noted, however, that these data were collected
from patients who were being treated with highly
myelosuppressive chemotherapy regimens and were
therefore at a greater risk for chemotherapy-
induced neutropenia. Consequently, these values do
not predict the risk of developing FN for all patients
with cancer.
The costs considered in this model are the total
cost of hospitalization for FN and the total cost of
CSF and are consistent with the costs used in our
earlier analysis [5]. The daily cost of hospitalization
of $1750 was determined from data from a cost-of-
illness study conducted at the H. Lee Mofﬁtt Cancer
Center [5]. Although these costs were based on data
from a single institution, these numbers are consist-
ent with estimates in the scientiﬁc literature. For
example, the estimated hospital cost per day from
an analysis of the discharge database of a consor-
tium of 115 academic centers reported that average
daily hospital cost increased from $1429 to $1828
between 1995 and 2000 [18]. The baseline esti-
mates of inpatient mortality were derived from clin-
 
Table 1
 
Talcott FN risk groups
 
Group Deﬁnition
Number of   
patients Mortality Risk Management
1 Patients with hematologic malignancies or after bone marrow
transplantation; already hospitalized at onset of  FN
268 9% High Inpatient
2 Outpatients with comorbidities such as pulmonary or
cardiovascular disease
43 12% High Inpatient
3 Outpatients without comorbidities but with uncontrolled cancer 29 14% High Inpatient
4 Clinically stable outpatients without comorbidities and with
responsive tumors
104 0% Low Outpatient
 
Data from Talcott et al. [16].
 
Table 2
 
Assumed values used in decision model to calculate overall costs of  FN treatment
 
Measure
Ranges from sensitivity 
analysis Assumed value Basis
Risk of  hospitalization for FN 0–1 0.55 Clinical trial data [17]
Risk reduction with CSF 0–1 0.50 Clinical trial data [17]
Mean hospitalization cost per day, ﬁxed and variable costs $500–$3000 $1750 Single-institution data [5]
Mean CSF cost per day $150–$500 $250 Single-institution data [7]
Proportion of  patients by risk
Low-risk patients 0.05–0.50 0.18 Single-institution data [5]
Mean hospital LOS Single-institution data [7]
High-risk patients 1–30 16.6 days
Low-risk patients 1–30 7.5 days
Mean duration of  CSF use 1–14 8 days Meta-analysis of  RCTs [6]
Inpatient mortality 0–10 8.1% Clinical trial data [17]
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ical trial data that reported a mortality of about 8%
in the control arm and the arm that received pro-
phylactic CSF [17]. The cost of CSF was based on
the charges for the agent of about $180 per day and
its administration (about $70 per day).
In the decision analytical model the expected cost
of a strategy was calculated as the sum of the prod-
ucts of the terminal value or cost and the probabil-
ity associated with each branch. The total cost of
hospitalization was the product of the average daily
cost of hospitalization and the average hospital
LOS. The total cost of CSF was the product of the
average daily cost of CSF and the number of days it
was used. The therapeutic choices evaluated were 1)
no CSF and inpatient treatment of FN; 2) prophy-
lactic CSF and inpatient treatment of FN; and 3)
prophylactic CSF and risk stratiﬁcation into high-
and low-risk categories with outpatient treatment
of low-risk patients. The model assumes that the
costs with the high-risk patients were the same as
the inpatient costs. It was assumed that low-risk
patients had a 48-h hospitalization for assessment
and the initiation of treatment, followed by outpa-
tient management of their FN.
Sensitivity analyses were performed in which one
or more of the model assumptions were varied
within a reasonable range of values. Threshold
curves were plotted by varying the risk for FN with
the LOS and with hospital costs per day.
 
Results
 
Patient stratiﬁcation into high- and low-risk groups
based on Talcott’s risk categories correlated well
with the average LOS. For the Albany Medical
Center data (n = 82), the mean LOS was much
shorter in low-risk patients than in high-risk
patients (7.5 
 
±
 
 2.3 vs. 16.6 
 
±
 
 3.6 days). The valida-
tion of the Talcott model was conﬁrmed in a larger
data set from the H. Lee Mofﬁtt Cancer Center
(n 
 
=
 
 1103), which yielded comparable results.
These durations of LOS were also consistent with
the results of an analysis of a large discharge data-
base of 115 academic institutions that included the
medical records of more than 41,000 patients.
Patients with a primary diagnosis of FN, compara-
ble to the low-risk group, had a mean LOS of
5.8 days compared to those patients with a second-
ary diagnosis of FN, comparable to the high-risk
group, who had a mean LOS of 17.0 days [18].
Incorporating the baseline probabilities and out-
comes into a cost-minimization model produced the
following estimates of costs per cycle: without pro-
phylactic CSF: $13,355; with prophylactic CSF but
without an outpatient option for FN: $8677; and
with prophylactic CSF and with an outpatient
option in low-risk patients: $8188 (Fig. 2).
We conducted a sensitivity analysis based on var-
iations in the risk of hospitalization for FN and the
LOS over a reasonable range of values, as shown in
Fig. 3A. A similar sensitivity analysis is shown for
 
Figure 2
 
Expected total treatment costs of  FN per cycle without
prophylactic CSF and with prophylactic CSF without and with an out-
patient treatment option.
 
Figure 3
 
Two-way sensitivity analysis based on previously reported
cost estimates [5] for FN risk thresholds without and with an outpa-
tient treatment option varying (A) LOS in low-risk patients and (B)
daily costs of  hospitalization.
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the risk threshold for FN over a reasonable range of
values for hospital costs per day (Fig. 3B). The area
above each curve represents the values of the vari-
ables that favor the prophylactic use of CSF. The
risk threshold for the prophylactic use of CSF
decreases as the LOS and hospital costs per day
increase.
The risk threshold for the cost-saving use of CSFs
is only slightly lower with the outpatient treatment
option. At an average daily cost of hospitalization
of $1750, the risk threshold for FN at which pro-
phylactic CSF becomes cost-saving is 16% when all
patients with FN are treated as inpatients; it
decreases to 15% when the low-risk patients are
treated as outpatients.
 
Discussion
 
Neutropenia remains the major dose-limiting toxic-
ity of cancer chemotherapy, and recombinant CSF
has had a major effect on the management of
patients treated with chemotherapy. Febrile neutro-
penia that is associated with chemotherapy causes
signiﬁcant morbidity and high mortality and
increases the overall costs of treatment. Prophylac-
tic CSF reduces the incidence and severity of FN,
thereby decreasing the costs of hospitalization.
The risk threshold for FN with prophylactic CSF
is the point at which the cost of the CSF is the same
as the reduction in the costs of hospitalization due
to its use. A cost-minimization threshold analysis
that used only direct hospital costs was used to pro-
duce the 40% risk threshold that has been widely
adopted to guide the use of CSF as primary proph-
ylaxis [19]. If additional indirect costs, such as the
cost associated with the loss of pay to the patient
and caregiver are included, the cost of managing FN
is much higher [11]. This increase in costs favors the
use of prophylactic CSF.
The outpatient treatment option for patients
with FN who are at low risk for serious medical
complications is assumed to lower the overall costs,
thereby potentially increasing the risk threshold at
which prophylactic CSF becomes cost-effective
[19]. The economic analyses in this study assessed
the overall costs of managing FN and calculated the
risk threshold at which prophylactic CSF becomes
cost-saving. According to these economic analyses,
this assumption may not be valid because the man-
agement of low-risk cases in the outpatient setting
has little or no effect on the economic model.
Rather, it is the high-risk cases that contribute sig-
niﬁcantly to the cost of treatment. As shown in this
study, the outpatient treatment option appears to
decrease, not increase, the risk threshold for cost
savings with prophylactic CSF, except in very short
hospitalizations. At an average cost of hospitaliza-
tion of $1750/day, the risk thresholds for inpatient-
only and the inpatient with low-risk outpatient
option were estimated at 16% and 15%,
respectively.
This ﬁnding appears to be related to the fact that
high-risk patients have a longer LOS and account
for the majority of patients admitted with FN and
low-risk patients have a shorter LOS and account
for a smaller number of patients. Thus, in this
model, the outpatient treatment option affected the
costs generated by relatively few patients, most of
whom would have had a short LOS.
The results of this economic analysis should be
validated in prospective population-based (cohort)
analyses in which the total costs in the entire pop-
ulation are estimated rather than in subgroup cost
analyses in patients treated in the outpatient and
inpatient settings. This model suggests that consid-
erable cost shifting is likely when the outpatient
management of FN is an option.
 
Conclusions
 
With careful selection and appropriate safeguards,
outpatient management of FN in truly low-risk
patients may be safe and may be associated with
improved quality of life. The results presented here
suggest, however, that such an approach may have
minimal economic impact. The risk thresholds for
FN for the cost-saving use of CSF are valid in prac-
tice settings in which the outpatient management of
FN is an option.
 
Source of ﬁnancial support: This study was supported by
an unrestricted educational grant from Amgen. Presented
in part at the 37th annual meeting of the American Soci-
ety of Clinical Oncology, San Francisco, California, May
12 to 15, 2001.
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